74
NAPROSYN (Naproxen) INTRODUCTION Naprosyn is a propionic acid derivative with, Rapid, reversible, competitive inhibition of cyclo-oxygenase enzyme, analgesic action, anti-inflammatory action, potent inhibitor of leukocyte migration has a long half life, PHARMACODYNAMICS Naprosyn is a non selective NSAIDs with anti- inflammatory, analgesic, and antipyretic effects. Naprosyn inhibits both COX-1 and COX-2 enzymes which are required for PGs synthesis. PHARMACOKINETICS Absorption Completely absorbed from gut Peak levels are achieved with 2 hours Less presystemic metabolism (< 5%) therefore high bioavailability Food slightly delays absorption with no effect on total absorption. Distribution Highly protein bound > 99%. Therefore less volume of distribution (0.91 lit/kg) Plasma half life - 12-15hrs Steady state concentration achieved within 3 days Binding to albumin is reduced in cirrhosis and in the elderly. Synovial fluid concentrations of naproxen increase from 50% of serum levels at 3 to 4h to 74% at 15h. A steady state therefore synovial fluid concentrations are equivalent to those in plasma. It crosses the placenta within 20 to 30 min of oral administration and appears in 1

Product Manual Acute

Embed Size (px)

Citation preview

Page 1: Product Manual Acute

NAPROSYN (Naproxen)

INTRODUCTIONNaprosyn is a propionic acid derivative with,

Rapid, reversible, competitive inhibition of cyclo-oxygenase enzyme,

analgesic action, anti-inflammatory action, potent inhibitor of leukocyte migration has a long half life,

PHARMACODYNAMICSNaprosyn is a non selective NSAIDs with anti-inflammatory, analgesic, and antipyretic effects. Naprosyn inhibits both COX-1 and COX-2 enzymes which are required for PGs synthesis.

PHARMACOKINETICSAbsorption

Completely absorbed from gut Peak levels are achieved with 2 hours Less presystemic metabolism (< 5%) therefore high bioavailability Food slightly delays absorption with no effect on total absorption.

Distribution Highly protein bound > 99%. Therefore less volume of distribution

(0.91 lit/kg) Plasma half life - 12-15hrs Steady state concentration achieved within 3 days Binding to albumin is reduced in cirrhosis and in the elderly.

Synovial fluid concentrations of naproxen increase from 50% of serum levels at 3 to 4h to 74% at 15h. A steady state therefore synovial fluid concentrations are equivalent to those in plasma. It crosses the placenta within 20 to 30 min of oral administration and appears in the milk of lactating women at approximately 1% of maternal plasma concentrations. Concentrations achieved in synovial fluid is half (52%) that of steady state plasma concentration

1

Page 2: Product Manual Acute

METABOLISM AND EXCRETION

Extensively metabolised in the liver. Metabolites are inactive (no anti-inflammatory effect, 10% excreted unchanged).

97-99% of naproxen and its metabolites excreted in urine and very small percentage excreted in feces.

ADVERSE DRUG REACTIONS

Gastrointestinal Heartburn, abdominal pain, nausea, dyspepsia, diarrhoea and

constipation. More common in elderly & sick (more in female) Depends on dose & duration (increases with both)

Skin Reactions Rash, Urticaria, Photosensitivity

Central Nervous System Headache, Dizziness, Drowsiness, Tinnitus

Renal systemLong term use leads to interstitial nephritis

INDICATIONS

Acute Conditions Relief from mild to moderate pain Acute musculo-skeletal disorders (eg. strains & sprains) Dysmenorrhoea Gout (Acute) Menorrhagia Migraine

Chronic Conditions Osteoarthritis (OA) Rheumatoid Arthritis (RA) Ankylosing Spondylitis Juvenile RA Chronic Pain States with inflammatory component

RECOMONDED DOSAGE

2

Page 3: Product Manual Acute

Acute conditions : 500 mg stat followed by 250 mg, 6h / 8h Max. daily dose > 1250 mg/ day.

Chronic conditions : 250 - 500 mg b.d. / 500 - 1000 mg single dose

Acute gout : 750 mg stat followed by 250 mg , 8h until attack subsides

Migraine (Acute attack) :750 mg at first symptom 250 - 500 mg additional half an hour later

Menorrhagia : First day 375 - 750 mg b.d. Later > 1000 mg/day

Children– Not recommended < 2 years; Maximum > 15 mg/kg/d – Juvenile Rheumatoid Arthritis, 10 mg/kg/day in 2 divided

doses– Analgesic / Antipyretic, initial - 10 mg/kg, later - 2.5-5

mg/kg/q8h

CONTRAINDICATIONS Hypersensitivity History of asthma, rhinitis, nasal polyps and with aspirin Active peptic ulcer/active GI bleeding Children < 2 yr.

PRESENTATION

Naprosyn 250mg - Each uncoated tablet contains Naproxen 250mgNaprosyn 500mg - Each uncoated tablet contains Naproxen 500mgStrip of 10 tablets

USPs OF NAPROSYN

Known agent Good analgesic / anti-inflammatory Long duration of action Once daily dosing possible One amongst most widely prescribed Non-aspirin NSAIDs

3

Page 4: Product Manual Acute

NAPROSYN SR

COMPOSITION

Naproxen Sustained Release Tablets 750mg

INTRODUCTION

Naproxen is a propionic acid derivative with, Rapid, reversible, competitive inhibition of Cyclo-oxygenase , Analgesic action, Anti-inflammatory action, Has a long half life, Potent inhibitor of leukocyte migration.

Naprosyn SR is a sustained release form of Naproxen. In Naprosyn SR Naproxen is released as 10 % immediate release and 90% over a period of 22hrs.

MATRIX TECHNOLOGY

Naprosyn SR involves hydrophilic Hydroxypropyl Methylcellulose [HPMC]The classification of matrix systems is based on matrix structure, release kinetics, controlled release properties (diffusion, erosion, swelling), and the chemical nature and properties of employed materials Matrix systems are usually classified in 3 main groups: hydrophilic, inert, and lipidic.

4

Page 5: Product Manual Acute

The matrix system has several advantages as follows,

1. It is very simple and easy to establish a stable formulation.2. The tablet is completely dissolved and thus achieves good bioavailability.3. Offers sustained release of drug with OD advantage

Figure 1 illustrates the schematic dissolution profile of the matrix tablet.

After administration, hydrophilic matrix tablets made with HPMC hydrate to form a gel layer, which regulates the drug release pattern. The most important aspect of this matrix system is the homogeneity of HPMC particle distribution in the tablet. The selection of HPMC grades affects the initial wetting, swelling, hydration and gel strength.

PHARMACOKINETICS

Absorption Naproxen is completely absorbed from GI tract & In-vitro bioavailability is

95%. Peak plasma level is attained after 1-2 hours of oral administration of IR

Tablets. Cmax of IR Tablets 97.4 meg/ml tmax of IR Tablets 1.9 hrs. Food slightly delays absorption with no effect on total absorption.

Distribution Highly protein bound > 99%. Vd is 0.16 It./kg Half life - 12-17hrs Steady state concentration achieved within 4-5 days Binding to albumin is reduced in cirrhosis and in the elderly. Synovial fluid

concentrations of naproxen increase from 50% of serum levels at 3 to 4h to 74% at 15h. A steady state therefore synovial fluid concentrations are equivalent to those in plasma. It crosses the placenta within 20 to 30 min of oral administration and appears in the milk of lactating women at approximately 1% of maternal plasma concentrations. Concentrations achieved in synovial fluid is half (52%) that of steady state plasma concentration

5

Page 6: Product Manual Acute

Metabolism and Excretion Extensively metabolized in the liver. Metabolites are inactive (no anti-

inflammatory effect It is metabolized to 6-0-desmethyl Naproxen. >95% of Naproxen is excreted in urine.

Adverse EffectsGI Effects - Average risk ++

- Elderly & sick (more in female) - Post-marketing studies (PMS) Napexar well tolerated when other NSAIDs are not. - Dose- & duration-dependent (increases with both)

Skin Reactions - Urticaria, Rash, Photosensitivity

PreparationsTablet Naprosyn SR 750mg

INDICATIONS - CHRONIC CONDITIONS

Rheumatoid Arthritis (RA) Osteoarthritis Ankylosing Spondylitis Pain due to fracture Back Pain Chronic Pain States with inflammatory component

DOSAGE

Once daily administration of the total daily dose of Naproxen required can be achieved by administering the appropriate Naprosyn SR tablet i.e. Naprosyn SR 750 mg.

Naprosyn SR tablets should be taken whole and not chewed. The total daily dose of Naproxen should not exceed 1000 mg.

Naprosyn SR TABLETS ARE NOT INTENDED FOR PATIENTS REQUIRING SHORT TERM TREATMENT FOR ACUTE INDICATIONS

CONTRAINDICATIONS

HypersensitivityHistory of asthma, rhinitis, nasal polyps within aspirin or other NSAIDsActive peptic ulcer/active GI bleedingChildren < 2 yr.

6

Page 7: Product Manual Acute

Satisfies all criteria of a good NSAID

Indication Pain Relief - Yes OA / RA - Yes Restricted Use - No Long Half-life - Yes Once Daily - Yes ADRs GI Irritation

Peptic UlcerCNS Effects Average Risk Tinnitus (++)HepatitisRenal Effects

USPs OF Naprosyn SR

Good analgesic / anti-inflammatory as Naproxen inhbits Cyclo-oxygenase Long duration of action as Naproxen has longer Half Life Once daily dosing possible due to Matrix technology Widely prescribed Non-aspirin NSAIDs-Time tested and trusted molecule

internationally.

Naprosyn SR FAQ

1.What is Naprosyn SR?Naprosyn SR is a sustained release form of Naproxen. In Naprosyn SR Naproxen is released as 10 % immediate release and 90% over a period of 22hrs.

2.What is the sustained release technology & what are their benefits?In Sustained release technology, the release of drug is modified in such a way that it maintains the levels of drug for a longer duration than the regular drug.The obvious benefit of sustained release drug is improved compliance of the patient.The drug level in the blood of the patient is adequate to provide the required pain relief or analgesia.

3.What is the matrix technology?Matrix is a mould in which a drug is embedded. The classification of matrix systems is based on matrix structure, release kinetics, controlled release properties (diffusion, erosion, swelling), and the chemical nature and properties of employed materials Matrix systems are usually classified in 3 main groups: hydrophilic, inert, and lipidicThe matrix system has several advantages as follows,

1. It is very simple and easy to establish a formulation.

7

Page 8: Product Manual Acute

2. The tablet is completely dissolved and thus achieves good bioavailability.3. Offers sustained release of drug with OD advantage

4.What is the polymer used in Naprosyn SR?Naprosyn SR involves hydrophilic Hydroxypropyl Methylcellulose [HPMC] as a polymer.

5.What are the indications & dosages of Naprosyn SR?In contrast to plain Naprosyn, the indications of Naprosyn SR are not acute but the maintenance of chronic conditions like Osteoarthritis, Rheumatoid arthritis etc. The usual dose is 750 mg once a day after meals. 6.What is duration of Naprosyn SR treatment?The duration of Naprosyn SR will be same as Naprosyn which has been used from 1 year to 4 years as per the clinical trials depending upon the need & tolerability of the individual patient. But the common principle of NSAID prescription applies here in which the drug has to be used for minimum possible time & if at all required to be used for longer duration, a gap of 15 days is given after 1 to 3 months along with monitoring his GI, Renal & Cardiac status.

7.What are the adverse events of Naprosyn SR?The adverse events of Naprosyn SR are same as that of plain Naprosyn.

8.What are the advantages of Naprosyn SR over Naprosyn?Both dosage formulations are important but the choice will depend upon the doctor to use it. Usually doctors prefer to write plain NSAID for acute conditions & sustained release for maintenance of chronic conditions.

9. What precautions are to be taken during Naprosyn SR treatment?Apart from the usual precautions which are taken for any NSAID prescription like history of the patient, allergy to NSAIDs in the patient etc, the most important thing during Naprosyn SR therapy is that the tablet should not be chewed but swallowed as a whole because if the tablet is chewed all the advantage of sustained release will be lost.

10. How Naprosyn SR acts for 24 hrs when the GI transit time in not more than 6 to 8 hrs?This is the most commonly asked question for all the sustained release formulations. There are two ways to answer this. First is the Bioequivalence study in which our drug is compared with the already available brand in the market and both of them show similar dissolution profile. Second logical answer which is commonly given is that because of the cellulose present in the polymer the drug sticks to the microvillus of the small intestine from where it is slowly absorbed into the circulation so that even if the food moves ahead the drug still remains in the small intestine.Thirdly , as the water , gastric & intestinal secretions enter inside the Hydrophilic Matrix, the polymer in the matrix swells

8

Page 9: Product Manual Acute

up. This displaces the drug (Naproxen) from the matrix. Intially there will be rapid release of the drug in the 1st hour (10%) and then there will be gradual release of the drug (90%) over a period of 24 hours. In the latter part, when all the drug is released, this matrix undergoes normal wear and tear as seen in any tablet (disintegration), and is excreted out in the faeces. There is no “Ghost Tablet” seen in faeces as is common with few SR preparations.

16.What are the other brands of Naprosyn SR available in the market?Following brands are available in the marketXenar CR (750 mg) by Elder pharmaceuticals

USPs of the Product Naproxen in Naprosyn SR is the S isomer which active form of Naproxen

molecule responsible for the analgesic effects. Naprosyn SR 10% immediate release and 90% sustained released over a

period of 24 hrs.Thus a sustained pain relief for 24 hrs. Once day dosage. Since Naproxen is released in the Intestine in small packets (small

Quantity) ,the GI side effects are much less . Naprosyn SR taken at night time assures pain relief at early morning hour

for the patients suffering from Rheumatoid arthritis and Osteoarthritis.Thus provides a Good pain free morning for patients suffering from Morning Sickness.

Lesser GI side effects and Convenient dosage schedule make it a drug of choice for chronic painful conditions.

9

Page 10: Product Manual Acute

Naprosyn Suspension

Juvenile arthritis (JA) refers to any form of arthritis or an arthritis-related condition that develops in children or teenagers who are less than 17 years of age.Impact of Juvenile Arthritis:• Nearly 300,000 children under the age of 17 are affected by juvenile arthritis• Juvenile rheumatoid arthritis (JRA), affecting 50,000 children, is the most common form of juvenile arthritis and one of the most common childhood diseases in the US.• Arthritis and related diseases, such as JA, cost the U.S. economy nearly $128 billion annually in medical care and indirect expenses, including lost wages and production

Common Symptoms of Juvenile Rheumatoid Arthritis:• Pain, swelling, tenderness and stiffness of joints, causing limited range of motion• Joint contracture, which results from holding a painful joint in a flexed position for an extended period• Damage to joint cartilage and bone leading to joint deformity and impaired use of the joint• Altered growth of bone and joints leading to short statureTypes of Juvenile Rheumatoid Arthritis:• Polyarticular JRA affects five or more joints and:o affects girls more frequently than boyso most commonly affects knees, wrists and ankleso can affect weight-bearing and other joints, including hips, neck, shoulders and jawo often affects the same joint on both sides of the body• Pauciarticular JRA affects four or fewer joints and:o usually affects the large joints: knees, ankles or wristso often affects a joint on one side of the body only, particularly the kneeo may cause eye inflammation (uveitis) which is seen most frequently in young girls with positive anti-nuclear antibodies (ANA)• Systemic Onset JRA can:

affect boys and girls equally cause high, spiking fevers of 103 degrees or higher, lasting for weeks

or even months cause a rash consisting of pale, red spots on the child’s chest, thighs

and sometimes other parts of the body cause arthritis in the small joints of the hands, wrists, knees and

anklesOther Types of Juvenile Arthritis:• Juvenile Spondyloarthropies (ankylosing spondylitis, seronegative enthesopathy and arthropathey syndrome) are a group of diseases that involve the spine and joints of the lower extremities, most commonly the hips and knees

10

Page 11: Product Manual Acute

• Juvenile Psoriatic Arthritis is a type of arthritis affecting both girls and boys that occurs in association with the skin condition psoriasis• Juvenile Dermatomyositis is an inflammatory disease that causes muscle weakness and a characteristic skin rash on the eyelids• Juvenile Systemic Lupus Erythematosus is an autoimmune disease associated with skin rashes, arthritis, pleurisy, kidney disease and neurologic movement• Juvenile Vasculitis is an inflammation of the blood vessels and can be both a primary childhood disease and a feature of other syndromes, including dermatomyositis and systemic lupus erythematosusCauses of Juvenile Arthritis:• The cause of most forms of juvenile arthritis is unknown, but it is not contagious and there is no evidence that foods, toxins, allergies or vitamin deficiencies play a role.Diagnosis of Juvenile Arthritis:• A diagnosis of juvenile arthritis is based on a complete medical history and careful medical examination. Evaluation by a specialist – either a pediatric rheumatologist or a rheumatologist – is often required• Laboratory studies including blood and urine tests are often needed to assist in a diagnosis of JA• Imaging studies including X-rays or magnetic resonance images may be needed to check for signs of joint or organ involvement in JAManagement of Juvenile Arthritis:• Management varies depending on the specific form of juvenile arthritis• Care by a pediatric rheumatologist is important for most forms of JA• The primary goals of treatment for juvenile arthritis are to control inflammation, relieve pain, prevent joint damage and maximize functional abilities• Treatment plans for children usually include medication, exercise, eye care, dental care and proper nutrition• Nonsteroidal anti-inflammatory drugs (NSAIDs) are the first line of medication used in juvenile arthritis to help control pain and inflammation• Disease-modifying anti-rheumatic drugs such as methotrexate are often used in conjunction with NSAIDs to treat joint inflammation and reduce the risk of bone and cartilage damage• Corticorticoids such as prednisone can be taken orally to relieve inflammation or injected into joints that are inflamed• Biologic Response Modifiers (BRMs) are a class of drugs that inhibit proteins called cytokines. They must be injected under the skin or given as an infusion in the vein

The Product:NAPROSYN suspension contains the active ingredient naproxen and belongs to a group of medicines called Non-Steroidal Anti-inflammatory Drugs (or NSAIDs)Composition:Naproxen 125 mg/5ml..

11

Page 12: Product Manual Acute

NAPROSYN suspension relieves pain and reduces inflammation (swelling, redness and soreness) that may occur in the following different types of arthritis including rheumatoid arthritis,osteoarthritis and ankylosing spondylitis, muscle and bone injuries such as sprains, strains, low back pain(lumbago), rheumatism and tendonitis, such as tennis elbow• swelling and pain after setting broken or dislocated bones• menstrual cramps (period pain)• headache, including migraines• following surgery• dental pain

Although NAPROSYN suspension can relieve the symptoms of pain and inflammation. NAPROSYN suspension is recommended for use in children (over the age of 5) for the treatment of juvenile rheumatoid arthritis.NAPROSYN suspension is not addictive. This medicine is available only with a doctor’s prescription.

Juvenile Rheumatoid ArthritisThe recommended dose for children 5years and above is 10 mg/kg given in 2 equal divided doses (i.e. 5 mg/kg twice a day).

USP of Naprosyn Suspension Naprosyn suspension is the only FDA approved NSAID for JRA

apart from Ibuprofen. Naproxen is available in suspension form for the first time in India. Better Safety profile than Ibuprufen. Available in tasty tuti-fruity flavor. Affordable price

12

Page 13: Product Manual Acute

RELIGEL (TOPICAL GEL)

PHARMACOLOGICAL ROLE OF EACH INGREDIENTS ROLE OF OLEUM LINI

Also called as linseed oil is extracted from the seed of the plant Linum usitatissium

PHARMACOLOGY

Linseed oil predominantly contains alpha linolenic acid, which has anti inflammatory activity. On topical application alpha linolenic acid is absorbed into the systemic circulation, on metabolism it produces Eicosapentaenoic acid (EPA), EPA in the presence of the enzyme cyclo-oxygenase and lipooxygenase gets converted into PGE3 and PGF3 and leukotriene LTA5, LTB6 & LTC5 respectively.

PGE3 is a relatively non-inflammatory prostaglandin while LTA5, LTB6 and LTC5

possesses1-10% of the inflammatory activity compared to that of leukotrines produced by arachidonic acid.Further the presence of EPA prevents the action of cyclo-oxygenase on arachidonic acid which reduces its conversion to PGE2. Although PGE3 is relatively non-inflammatory but it still acts as a useful negative feedback regulator to modulate the inflammatory responses and reduce the production of PGE2

- linolenic acid Eicosapentaenoic acid (EPA)

PGE3

Leuktrines (LTA5, LTB5,

LTC5)

Arachidonic acid PGE2

Thus alpha linolenic acid possesses anti-inflammatory activity by decreasing the formation of PGE2 by producing relatively non inflammatory PGE3

By producing PGE3 which acts as a negative feedback regulator to reduce the conversion of arachidonic acid to PGE2.

ROLE OF DICLOFENAC DIETHYLAMMONIUM

Diclofenac diethylammonium is a clinically proven topical NSAID in the treatment of pain and inflammation associated with musculoskeletal disorders.

13

COX Lipooxygenase

COX

- ve

Page 14: Product Manual Acute

PHARMACOLOGY

Diclofenac exhibits its anti-inflammatory activity by dual mode of action. It prevents the conversion of arachidonic acid to PGE2 by inhibiting the enzyme cyclo-oxygenase. More over it also enhances the uptake of arachidonic acid into the phospholipid pool.The uptake of AA into the phospholipid pool limits the availability of AA into the lipo-oxygenase pathway the resultant effect is a decrease in PGE2 and LTB4 which together effectively counteracts the clinical signs and symptoms of inflammation. Thus Diclofenac and alpha linolenic acid work synergistically.

ROLE OF METHYL SALICYLATE

Methyl Salicylate is used topically as a counter irritant. on topical application it is absorbed through the skin and is applied for the relief of pain in rheumatic conditions and painful muscles and joints.

ROLE OF MENTHOL

On topical application menthol dilates the blood vessels causing a sensation of coldness followed by an analgesic effect. Menthol also acts as a penetration enhancer. It increases the penetration of the drugs when applied on the skin to give a faster onset of action. Menthol acts as a penetration enhancer either due to its vasodilation property or as it readily penetrates the skin.

PHARMACOKINETICSRapidly and completely absorbed from skin90% reversibly bound to plasma protein Plasma half life (t ½) - 2 hrsMetabolized in liver65% drug is excreted in urine35% in bileGood tissue concentration in synovial fluid(93 times longer than in plasma)

ADVERSE DRUG REACTIONS

G.I. TractOccasional : Epigastric pain, nausea, vomiting, diarrhoea, abdominal cramps,

Dyspepsia, flatulence and anorexiaRare : GI bleeding, peptic ulcer, bloody diarrhoea

Central Nervous SystemOccasional : Headache, light headedness/vertigo

14

Page 15: Product Manual Acute

Rare : Drowsiness

SkinOccasional : RashesHypersensitivity: Rare

LiverOccasional : Elevation of serum aminotransferasesRare : Hepatitis with/without jaundice

CONTRAINDICATIONS

Peptic ulcer Hypersensitivity to Diclofenac/Aspirin Attack of asthma, urticaria precipitated by aspirin or other NSAIDs.

PRESENTATION

Religel - 30gm tube in printed carton

15

Page 16: Product Manual Acute

Cefixime

Nufex-beta(Cefixime+Clavulanate)

Description :

Cefixime is a white to light yellow powder. Slightly soluble in water,soluble in methanol.Cefixime is an oral betalactam antibiotic in a class of drugs called cephalosporin’s. Cefixime is the third generation cephalosporin. Cefixime fights bacteria in the body. Cefixime is used to treat many different types of bacterial infections.

Molecular Formula: C16H15N5O7S2

Molecular Weight: 453.452 g/mol

Clavulanic acid is a beta-lactamase inhibitor sometimes combined with penicillin group antibiotics to overcome certain types of antibiotic resistance. It is used to overcome resistance in bacteria that secrete beta-lactamase, which otherwise inactivates most penicillin’s.

The name is derived from the Streptomyces clavuligerus, which produces clavulanic acid. Clavulanic acid is biosynthetically generated from the amino acid arginine and the sugar glyceraldehyde 3-phosphate.

Molecular Formula: C8H9N O 5

Molecular Weight: 199.16g/mol

MOA of Cefixime

Cefixime inhibits cell wall synthesis in actively dividing microbial cells.As the shape & structure of Β-lactams resembles with the peptide chains & hence does not allow the cross linkage of cell wall & makes the cell wall fragile.

MOA of Clavulanic acid

16

Page 17: Product Manual Acute

Clavulanic acid has negligible antimicrobial activity. Clavulanic acid act as a competitive inhibitor of beta-lactameses, an enzyme which destroys the beta-lactam ring of the cefxime. If this beta-lactam ring is destroyed , then cefixime will not be able to inhibit the cell wall synthesis of the organism.

Pharmacology

CefiximeBioavailability 40% to 50% Protein binding approximately 60%Metabolism ?Half life Variable Average 3 to 4 hoursExcretion Renal and biliary (add %)

Clavulanic acidBioavailability well absorbed Protein binding ?Metabolism Hepatic (extensive)Half life 1 hourExcretion Renal (30–40%)

Spectrum

Cefixime in Nufex-Beta offers wide coverage against majority of gram (+) ve, gram (-) ve, & anaerobic bacteria.

Gram (+) ve Gram (-) ve Anaerobes S.Pneumoniae E.coli Mycoplasma pneumoniae

S,Pyogenes H.Influenzae Mycoplasma hominis

S.Epidermidis M.Catarhallis Bacteroides fragilis

Clostridium Tetani Salmonella Fusobacterium

Corynebacterium Dip. Shigella Peptococcus sp

Neiserria gonorrhoeae

P.Mirabillis

Moreover addition of clavulanic acid to cefixime increases the– Anti-staphylococcal activity of cefixime

17

Page 18: Product Manual Acute

– Gram negative activity comparable to most cephalosporins.– Anaerobic activity comparable with metronidazole and better than

clindamycin.– Coverage against (ß-lactamase-producing strains of various gram

negative and positive organisms.

Indication:Pharyngitis Tonsillitis Otitis mediaSinusitisAcute bronchitisPneumoniaTyphoidAcute uncomplicated PylonephritisCystitis Urethritis Uncomplicated Gonorrhea

ContraindicationNufex Beta is contraindicated in patients with known allergies to the cephalosporin or penicillin antibiotics. Precaution If an allergic reaction to Nufex Beta occurs, the drug should be discontinued, and, if necessary, the patient should be treated with appropriate agents, e.g., pressor amines, antihistamines, or corticosteroids.Nufex Beta should be prescribed with caution in patient with history of gastrointestinal disease.Renal Impairment:Nufex beta may be administered in the presence of impaired renal function, but dose modification is recommended for patients with moderate or severe renal impairment (i.e., creatinine clearance of < 40 mL/min).

Adverse Drug ReactionHeadaches, Dizziness, Diarrhea , Stool changes ,Nausea , Abdominal pain , Dyspepsia Flatulence and Vomiting. Transient elevations of SGPT, SGOT and alkaline phosphatase.Transient elevations in Blood Urea Nitrogen (BUN) or creatinine.Skin rashes, Drug fever and pruritus. Anaphylactic reactions (urticaria and angioedema) have been reported rarely.

Dosage & administrationAdults:The recommended dose of cefixime Nufex beta is 400 mg once daily. When necessary, a dose of 200 mg (one-half of a 400 mg tablet) given twice daily may

18

Page 19: Product Manual Acute

be considered except for urinary tract infections where once daily dosing must be used.For treatment of uncomplicated gonococcal infections, a single oral dose of 400 mg is recommended.

Children:The recommended dose of cefixime in Nufex beta is 8 mg/kg/day once daily. When necessary, a dose of 4 mg/kg given twice daily may be considered except for urinary tract infections where once daily dosing must be used.

Rationale for a beta lactam-beta lactam inhibitor combination antibioticAs the usage of cephalosporin’s has increased globally the resistance to this group of antibiotic has also increased.Hence to overcome this resistance a Combination of cephalosporin’s with beta lactamase inhibitors is an attractive preposition for following reasons.

Production of beta lactamase is the most common mechanism of resistance to beta lactam antibiotics, especially in gram negative bacteria.

Convenience of use and more essentially an understanding that using such combination empirically may help in not only overcome therapeutic failures due to resistant bacteria but will also delay resistance development in susceptible bacteria.

Minimize use of newer antibacterial so that they remain effective antibacterial for specific use.

Has a broad spectrum antibiotic activity. Highly effective combination in switch therapy Well established safety and efficacy profile

Nufex-Beta in Pneumonia

Pneumonia is an inflammatory illness of the lung. Frequently, it is described as lung parenchyma/alveolar inflammation and abnormal alveolar filling with fluid.Cause- Pneumonia can result from a variety of causes, including infection with

bacteria, viruses, fungi, or parasites, and chemical or physical injury to the lungs.

Symptoms- Cough producing greenish or yellow sputum, or phlegm. High fever that may be accompanied by shaking chills. Shortness of breath Chest pain,

19

Page 20: Product Manual Acute

Cough up blood, Loss of appetite Blueness of the skin, nausea, vomiting

Pathophysiology:The most common causes of pneumonia are viruses and bacteria. Less common causes of infectious pneumonia are fungi and parasites.

Virus: Influenza virus,

Bacteria: Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa and Moraxella catarrhalis. Chlamydophila pneumoniae, Mycoplasma pneumoniae, and Legionella pneumophila

Clinical classification

Community-acquired pneumonia

Community-acquired pneumonia (CAP) is infectious pneumonia in a person who has not recently been hospitalized. CAP is the most common type of pneumonia. The most common causes of CAP include Streptococcus pneumoniae, viruses, the atypical bacteria, and Haemophilus influenzae. Overall, Streptococcus pneumoniae is the most common cause of community-acquired pneumonia worldwide.

Hospital-acquired pneumonia

Hospital-acquired pneumonia, also called nosocomial pneumonia, is pneumonia acquired during or after hospitalization for another illness or procedure with onset at least 72 hrs after admission. The causes, microbiology, treatment and prognosis are different from those of community-acquired pneumonia. Up to 5% of patients admitted to a hospital for other causes subsequently develop pneumonia. Hospital-acquired microorganisms may include resistant bacteria such as MRSA, Pseudomonas, Enterobacter, and Serratia.

Why Nufex-Beta in pneumonia?

20

Page 21: Product Manual Acute

1.Cefixime in Nufex-beta is having very low mic against most common pathogen responsible for causing pneumonia hence achieve high kill rate & better cure rate.

  H. influenzaea M.catarrhalis S.pneumoniae

Cefuroxime 2 2 0.12

Cefixime 0.13 .40 0.29

Cefpodoxime 0.12 0.50 .03

Co – amoxy clav

0.5 0.5 0.02

2. As per American Family Physician when clinician cause of concern is Beta lactamase positive H.Influenzae the first drug of choice is cefixime.

3. As per Clinical Drug Investigation The concentrations of cefixime found in bronchial mucosa exceeded these MIC90 values 4.3 ± 0.6 hours after the last dose. However, 8 hours after a 400mg oral dose, lung parenchyma concentrations were higher than MIC90 values for sensitive strains. This ensures better cure with cefixime as compared with other cephalosporins.

4. The majority of pathogens causing acute bacterial LRTIs are primarily located extracellularly, and for this reason there is a consensus that antibiotics should be present in the extra cellular fluid. The concentration of cefixime in ECF exceeds the mic of common respiratory pathogen & ensures better cure & concentrations of cefixime in ECF is sufficient to inhibit H. influenzae and S. pneumoniae.

5. As per Chemotherapy 1998 Cefixime is one such agent, which possesses excellent efficacy against a broad spectrum of pathogens, including Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis. Clinical success rates are similar to cefaclor, clarithromycin, and other cephalosporins. Importantly, cefixime also possesses excellent activity against beta-lactamase-producing strains.

6. Cefixime is the most preferred drug as a switch therapy as it offers coverage & efficacy at par with most intravenous agent.

Bacterial Species

Cefotax Ceftizox Ceftaz Ceftriax Cefixime

S. aureus 2 16 16 4 17

S. pneumoniae < 0.1 0.1 0.5 0.08 .29

S. pyogenes 0.1 0.25 0.12 0.1 .16

21

Page 22: Product Manual Acute

E. Coli 0.1 0.25 0.5 0.1 .71

Klebsiella spp. < 0.5 0.25 0.5 0.1 .34

7. More over addition of clavulanic acid in Nufex-beta make cefixime more effective against:

1. Staph. Aureus2. Gram (-) ve & anaerobic bacteria.

Nufex-Beta in Otitis media

Why Nufex-Beta in Otitis media?

1. Cefixime in Nufex-beta is having very low mic against most common pathogen responsible for causing otitis media hence achieve high kill ratio & better cure rate.

  H. influenzaea

M.catarrhalis S.pneumoniae

Cefuroxime 2 2 0.12

Cefixime 0.13 .40 0.29

Cefpodoxime 0.12 0.50 .03

Co – amoxy clav

0.5 0.5 0.02

2. Cefixime is an extended spectrum cephalosporin that has been shown to be more effective than amoxicillin in treating OM caused by Haemophilus influenzae. (Pediatr. Infect. Dis. J., 13, S30 (1994). )

3. Amoxicillin-clavulanic acid is having excellent coverage against S. pneumoniae but major concern is diarrhea which affects the compliance.

4. Amoxicillin-clavulanic exhibit inoculum effect whereas cefixime do not exhibit inoculum effect.

5. AOM is likely to be caused by betalactamase-producing Haemophilus influenzae or Moraxella catarrhalis & Two beta-lactamase-stable agents commonly used for empirical treatment of AOM are amoxicillin/clavulanate and cefixime. Studies has demonstrated that CFX has comparable clinical efficacy and a better adverse events profile than A/C when used to treat AOM of childhood. (Pediatric Drugs )

22

Page 23: Product Manual Acute

23

Page 24: Product Manual Acute

Nufex-beta in Typhoid

Why Nufex-Beta in Typhoid?

The mic required for cefixime is very low as compared to co-amoxyclav & other cephalosporin.

Molecule micCefixime 0.21mcg/mlAmoxy-clav 1mcg/mlCefuroxime axetil 4mcg/mlOfloxacin 0.12 mg/l

The conc. Of cefixime in gall bladder & spleen is higher as compared to other antibacterial. This will prevent the chance of further relapse.

Organ Concentration of CFX mic for salmonellaSerum 2.98 micrograms/ml 0.21mcg/mlGallbladder 25.02 micrograms/g 0.21mcg/mlBiliary level 8.8 micrograms/ml 0.21mcg/ml

Temp. defervescence will take by 4-5 day as compared to 6-7 day with co-

amoxyclav & other cephalosporin. This will reduce the duration as well cost of therapy.

Cefixime showed excellent activity against all 73 strains with an MIC90 value of 0.25 mcg/ml. Reflecting its high beta-lactamase stability, cefixime also had excellent activity against beta-lactamase-producing amoxicillin-resistant strains. Antibacterial activity of cefixime was comparable to ceftriaxone, ofloxacin, and ciprofloxacin, which are often used for the treatment of typhoid fever. clinical data, which showed that oral cefixime provides a safe and effective alternative for the treatment of typhoid fever, even in cases of multidrug-resistant S. typhi.

(J Infect Chemother. 1999 )

24

Page 25: Product Manual Acute

Nufex-Beta in UTI

Nufex-beta in UTI:

Cefixime Ofloxacin Amoxy-clav

Escherichia coli (90%)

0.71 0.12 8

Ureaplasma urealyticum

0.71 2 2

Neisseria gonorrhoeae

0.06 0.06 0.71

Chlamydia trachomatis

0.50 0.5 1

Mycoplasma hominis 0.80 1 4

Klebsiella pneumoniae

0.10 0.2 4

Proteus mirabilis 0.06 0.2 4

25

Page 26: Product Manual Acute

NUFEX

INTRODUCTION

Nufex contains Cephalexin which belongs to first generation Cephalosporin, oral administration. It is a semi-synthetic analog of Cephalosporin.

PHARMACODYNAMICS

Inhibition cell wall synthesis of bacteria.

PHARMACOKINETICS

Nufex is acid stable and may be given without regard to meals. It is rapidly absorbed after oral administration.

Nufex following doses of 250 mg, 500 mg, and 1 g, average peak serum levels of approximately 9, 18, and 32 μg/ml respectively were obtained at 1 hour.

Measurable levels were present 6 hours after administration. Nufex is excreted in the urine by glomerular filtration and tubular secretion.

Studies showed that over 90% of the drug was excreted unchanged in the urine within 8 hours.

During this period, peak urine concentrations following the 250 mg, 500 mg, and 1 g doses were approximately 1000, 2200, and 5000 μg/ml respectively

ANTIBACTERIAL ACTIVITY

Aerobes, Gram-positive Aerobes, Gram-negative:

Staphylococcus aureus (including penicillinase-producing strains).Staphylococcus epidermidis (penicillin-susceptible strains).Streptococcus pneumoniae.Streptococcus pyogenes

Escherichia coli.Haemophilus influenzae.Klebsiella pneumoniae.Moraxella (Branhamella) catarrhalis.Proteus mirabilis.

INDICATIONS

Nufex is used as a bactericidal agent against a wide range of Gram +ve and Gram-ve organisms. It does not possess activity against Pseudomonas

26

Page 27: Product Manual Acute

aeruginosa or Mycobacterium tuberculosis. It is indicated for the treatment of the following conditions, when caused by susceptible bacteria.

a. Respiratory tract infections - Acute and chronic bronchitis, bronchopneumonia and infected bronchiectasis.

b. Ear, nose and throat infections - Otitis media, mastoiditis, sinusitis, follicular tonsillitis and pharyngitis.

c. Urinary tract infections - Acute and chronic pyelonephritis, cystitis and prostatitis, prophylaxis of recurrent urinary tract infections.

d. Gynaecological and obstetrical infectionse. Skin, soft tissue, bone and joint infectionsf. Gonorrhoea, syphilis and prophylaxis in dental procedures (when penicillin is

unsuitable) g. Other infections including septicaemia and endocarditis.

CONTRAINDICATIONS

It is contraindicated in patients with known hypersensitivity to cephalosporins.

RECOMMENDED DOSAGE

ADULTS

The dosage ranges from1-4g daily in divided doses. For skin and soft tissue infections, streptococcal pharyngitis and mild, uncomplicated urinary tract infections, the usual dosage is 250mg every 6 hours, or 500mg every 12 hours. Cystitis therapy should be continued for 7-10 days. For most acute infections, treatment should continue for at least 2 days after symptoms have subsided. In severe systemic infections doses upto 4g/day can be used. In chronic recurrent or complicated urinary tract infections and syphilis, 500mg cephalexin should be given every 6 hours for two weeks.

Gonorrhoea - a single dose of 3g with 1g probenecid for males or 2g with 0.5g probenecid for females is usually effective.

CHILDREN

Usual recommended dose in divided doses is 25-50mg/kg/day for most-infections and upto 100mg/kg/day for chronic, severe or deep-seated infections. For skin and soft tissue infections, streptococcal pharyngitis and mild, uncomplicated urinary tract infections, total daily dose may be administered every 12 hours.

27

Page 28: Product Manual Acute

For most infections dosage schedule suggested is:

Neonates : 62.5 - 125mg bid1-5 yrs : 125mg tid6-12 yrs : 250mg tid

In severe infections dosage may be doubled. In otitis media, dose of 75-100mg/kg/day in 4 divided doses may be required.

In treatment of beta hemolytic streptococcal infections, therapeutic dose is to be administered for atleast 10 days.

IN RENAL FUNCTION IMPAIRMENT

When renal function is impaired the dosage of cephalexin should be reduced to prevent accumulation as follows:

The dosing intervals should be longer. The following guidelines for approximate dosing intervals are recommended:

Creatinine Clearance (ml/min)

50 50-20 20

Approximate dosing intervals for 500mg

8h 12h 24h

The maximum dosage given in the table should not be exceeded:

Creatinine Clearance (ml/min)

MAXIMUM DOSAGE

Adults (g/day) Children (mg/kg/day)

20-50 3.0 505-20 1.5 25 5 0.5 8

28

Page 29: Product Manual Acute

In patients on intermittent haemodialysis, an additional dose of 500mg at the end of each dialysis is recommended in addition to the daily dose.

ADVERSE DRUG REACTIONS (ADRs)

The common side effects with Nufex are diarrhoea, nausea and vomiting. Headache, dizziness, allergic reactions and raised serum transaminase levels have also been reported. Eosinophilia and very rarely neutropenia, which is reversible, have occured in a few patients.

As with other broad spectrum antibiotics overgrowth of Candida and rare instances of pseudomembranous colitis can occur.

PRESENTATIONNufex 250mg/500mg - Each tablet contains Cephalexin 250mg/500mgStrip of 10 tablets

29

Page 30: Product Manual Acute

NUFEX SR (CEPHALEXIN)

COMPOSITION

NUFEX SR 375

Each sustained release film coated tablet contains :

Cephalexin I.P. 375 mg(on anhydrous basis)

NUFEX SR 750

Each sustained release film coated tablet contains :

Cephalexin I.P. 750 mg(on anhydrous basis)

INDICATIONS

Cephalexin is used as a bactericidal agent against a wide range of Gram +ve and Gram-ve organisms. It does not possess activity against Pseudomonas aeruginosa or Mycobacterium tuberculosis. It is indicated for the treatment of the following conditions, when caused by susceptible bacteria.

a. Respiratory tract infections - Acute and chronic bronchitis, bronchopneumonia and infected bronchiectasis.

b. Ear, nose and throat infections - Otitis media, mastoiditis, sinusitis, follicular tonsillitis and pharyngitis.

c. Urinary tract infections - Acute and chronic pyelonephritis, cystitis and prostatitis, prophylaxis of recurrent urinary tract infections.

d. Gynaecological and obstetrical infectionse. Skin, soft tissue, bone and joint infectionsg. Gonorrhoea, syphilis h. Prophylaxis in dental procedures (when penicillin is unsuitable) h. Other infections including septicaemia and endocarditis.

CONTRAINDICATIONS

It is contraindicated in patients with known hypersensitivity to cephalosporins.

30

Page 31: Product Manual Acute

DOSAGE AND ADMINISTRATION

The sustained release tablets should not be cut, crushed or chewed but should be swallowed whole with a glass of water.

Usual Adult Dosage :

750 mg twice daily. In milder infections, 375 mg twice daily may be given.In severe infections, 2 tablets of 750 mg two times daily may be given. A maximum dose of 4 g/day should not be exceeded.

NOTE :

375 mg Cephalexin sustained release tablet administered twice a day is clinically equivalent to 250 mg Cephalexin conventional release tablet administered thrice a day.

750 mg Cephalexin sustained release tablet administered twice a day is clinically equivalent to 500 mg Cephalexin conventional release tablet administered thrice a day.

IN RENAL FUNCTION IMPAIRMENT

No dosage adjustments are essential for patients with a creatinine clearance greater than 50 ml/min. For patients with renal dysfunction, or renal failure dosage should be reduced.

SIDE EFFECTS

The common side effects with cephalexin are diarrhoea, nausea and vomiting. Headache, dizziness, allergic reactions and raised serum transaminase levels have also been reported. Eosinophilia and very rarely neutropenia, which is reversible, have occurred in a few patients.

As with other broad spectrum antibiotics overgrowth of Candida and rare instances of pseudomembranous colitis can occur.

PRECAUTIONS

Cephalexin should be administered with caution in the presence of markedly impaired renal function. Dosage of cephalexin in such cases should be suitably reduced.

31

Page 32: Product Manual Acute

In patients receiving cephalexin, false positive reaction for glucose in the urine may occur with copper reduction reagents (Benedict’s or Fehling’s solution or with ‘Clinitest’ but not with enzyme based tests, e.g. ‘Clinistix’).

Positive direct Coomb’s tests have been reported during treatment with cephalosporin antibiotics.

Generally cephalexin is well tolerated by patients sensitive to penicillin but as cross reactions have been encountered rarely, cephalexin should be given cautiously to penicillin sensitive patients.

Use of any drug in women of child bearing potential requires that the benefits of the therapy be weighed against possible hazards to the mother and foetus. However, laboratory and clinical experience to date has shown no evidence of teratogenicity.

OVERDOSAGE

Serum levels of cephalexin can be greatly reduced by peritoneal dialysis or haemodialysis.

STORAGE

In a cool, dry place.

32

Page 33: Product Manual Acute

Qugyl-OComposition :

Each tablet of Qugyl-O offers:Ofloxacin- 200mgOrnidazole-400mg

Description

Ofloxacin is a synthetic broad-spectrum antimicrobial agent for oral administration.

The chemical structure is:

Its empirical formula is C18H20FN3O4, Ofloxacin is considered to be soluble in aqueous solutions with pH between 2 and 5. It is sparingly to slightly soluble in aqueous solutions with pH 7 and freely soluble in aqueous solutions with pH above 9. Ofloxacin has the potential to form stable coordination compounds with many metal ions.

Ornidazole is a 5-nitroimidazole derivative drug which has antimicrobial action. It is used in the treatment of protozoal infections,and also in the treatment and prophylaxis of anaerobic bacterial infections. The chemical structure is

Formula: C7H10Cl N 3O3 

MOA Of ofloxacin:Ofloxacin is a DNA gyrase inhibitor. DNA gyrase is an essential bacterial enzyme that maintains the superhelical structure of DNA. DNA gyrase is required for DNA replication and transcription, DNA repair,

33

Page 34: Product Manual Acute

MOA of Ornidazole: The antimicrobial activity of ornidazole is due to the reduction of the nitro group to a more reactive amine that attacks microbial DNA, brings about loss of helical structure of DNA and subsequent DNA breakage thus inhibiting further synthesis and causing degradation of existing DNA.

Pharmacology:Ofloxacin:

Protein binding 32%Half life 9hrMetabolism ?Excretion Primarily urine (as unchanged drug)Bioavailability 98%

Ornidazole:

Protein binding 11 to 13%.Half life 13hrMetabolism Metabolised via the liver, excreted in the

Urine and FecesExcretion 85% of single oral dose is eliminated

with 5 days - Urine (63%) and Feces (22%)

Bioavailability More than 90%

Spectrum of Ofoxacin Ofloxacin being a second generation quinolone offers strong coverage

against Gram (-)ve pathogen including Pseudomonas species, Gram (+)ve and some atypical pathogen.

Acinobacter, Citrobacter,Enterobacter,E. coli,H. influenza, K. pneumonia,Proteus species,

Pseudomonas species,Serratia marcescsns,Enterococcus faecalis,Staph aureus,Strep. pneumonia.

It is also active against Propionobacterium acne and Chlamydia.

Spectrum of Ornidazole:

Ornidazole is active against a large number of anaerobic organisms including:Bacteroides fragilis, prevotellia, Fusobacterium,Gardenellla,Peptococcus,Clostridium species, and Eubacterium. Ornidazole is also effective against human parasitic protozoa like Entamoeba histolytica and Giardia lamblia.

34

Page 35: Product Manual Acute

Indication:Polymicrobial infections (Mixed infections) such as –

Diarrhea and dysentery of bacterial, protozoal and mixed origin Intra-abdominal infections Post operative infections Pelvic infections Pelvic inflammatory disease Diabetic foot ulcers Skin and skin structure infections

Contraindication:

Hypersentivity to quinolone or nitroimidazoles

Precaution & Side effect:

Generally ofloxacin plus ornidazole combination is well tolerated but very few patients can feel the side effects like dizziness, nausea, diarrhea, vomiting, abdominal pain and discomfort, headache, restlessness, and urticaria etc.Impaired renal or hepatic infection, alcohol intake, convulsions, avoids drinking or operative heavy machinery.Contraindicated

Dose:One tablet twice daily.

Talking points:

Broad spectrum: Ofloxacin & Ornidazole in Qugyl-O offers coverage against broad range of pathogen which includes gram(+)ve, gram(-)ve & anaerobes.

High bioavailability Serum concentration above MICs Negligible bacterial resistance reported High renal excretion as unchanged drug Longer half life BD dosing No taste alterations (unlike Tinidazole & Metronidazole) Negligible adverse events.

Competitor:

Brand Company Brakke Franco IndiaO2 Medley Oflatoon-OZ Zy.CadilaZenflox-OZ Mankind

Rabee

35

Page 36: Product Manual Acute

Composition Each enteric coated Rabee 20mg tab.Contains: Rabeparazole sodium 20mg

DescriptionRabeprazole is an oral drug that is used for the treatment of conditions caused by acid. It is in a class of drugs called proton pump inhibitors or PPIs. Other drugs in the same class include lansoprazole, omeprazole, pantoprazole ,and esomeprazole .

MOARabee act by irreversibly blocking the hydrogen/potassium adenosine triphosphatase enzyme system (the H+/K+ ATPase, or more commonly just gastric proton pump) of the gastric parietal cell. The proton pump is the terminal stage in gastric acid secretion, being directly responsible for secreting H+ ions into the gastric lumen, making it an ideal target for inhibiting acid secretion.

Targeting the terminal-step in acid production, as well as the irreversible nature of the inhibition, results in up to 99% reduction of gastric acid secretion.

Pharmacology

Bioavailability: 52%Absorption: Rabeprazole may be taken without regard to timing of meals.Protein Binding: 96.3% Excretion: Approximately 90% in urine, 10% in the feces.

Metabolism HepaticHalf life 1 - 1.5 hoursExcretion Renal

Indication gastric ulcer peptic ulcer (PUD) Maintenance of Healing of Erosive or Ulcerative GERD Healing of Erosive and Ulcerative GERD Healing of Duodenal Ulcers. Treatment of Symptomatic GERD Treatment of Pathological Hypersecretory conditions (Zollinger-Ellison) Helicobactor Pylori Eradication to Reduce Risk of Duodenal Ulcer

Recurrence

Contraindication

Hypersensitivity to Rabeprazole, substituted benzimidazoles or any of components of its pharmaceutical forms.

Pregnancy & lactation

Drug to drug interaction

36

Page 37: Product Manual Acute

Potentiates action of warfarin, Causes accumulation of cyclosporine,

reduces the absorption of ketoconazole and increases the absorption of digoxin.

Adverse Drug Reaction In clinical trials the most common side effect assessed as possibly or

probably related to Rabeprazole was Headache in 2.4% of patients vs 1.6% taking placebo.

diarrhea vomiting nausea abdominal pains constipation dry mouth increased or decreased appetite headache anxiety achlorhydria

Dosage & Administration

Indication Dose

GERD in adults 20 mg daily for 4-8 weeks & If healing does not occur after 8 weeks, another 8 week course may be considered. The recommended maintenance dose is 20 mg daily.

Heartburn 20 mg daily for 4 weeks and an additional 4 weeks if symptoms do not resolve.

Ulcers 20 mg daily for 4 weeks

Zollinger-Ellison Syndrome 60-80 mg daily

For eradication of Helicobacter pylori rabeprazole 20 mg, clarithromycin 500 mg, amoxicillin 1000 mg all given twice daily (morning and evening) for 7 days

Tablets should be swallowed whole and should not be crushed, split or chewed. Rabeprazole can be taken with or without meals since food has little effect on its absorption.

USP’S OF RABEE Based on the experimental and clinical evidence, following are the USP’s of RABEE.

Quick onset of action

37

Page 38: Product Manual Acute

Apart from acid inhibition, It also offers additional cytoprotective benefits by

significantly augmenting production of gastric mucus and mucin Greater antisecretory effect over 24 hr period than omeprazole,

esomeprazole and lansoprazole Significantly better control of day as well as night time heartburn

symptoms compared to placebo and omeprazole Significantly more effective than placebo in relieving heartburn and various

other gastrointestinal symptoms in non erosive GERD Effective long term ( upto 2 years) maintenance of healing and prevention

of symptoms in patients with healed GERD Achieved eradication rates of >85% as a part of triple therapy in

management of H. pylori eradication Low propensity for drug interactions Well tolerated during long term (upto 2 years) studies Bioavailability not

affected by food. Can be taken irrespective of meal timings

Competitor

Direct competitor Indirect competitorBrand Company Brand companyRazo DRL Lanzap DRLRablet Lupin Lanzofast Zydus Happi G. Remedies Splanz Sun Rabeloc Cadila Olit Cadila Rabicip Cipla Pantocid Sun

What is the evidence in favour of Rabee providing additional cytoprotection?Rabeprazole is a unique PPI in providing added cytoprotective action by enhancing mucus production and by increasing viscosity translating to cytoprotection provided to mucosa cells. This action may be responsible for superior healing rates and maintenance of healing with Rabeprazole.Rabeprazole has unique pharmacological property of augmenting the production of gastric mucus and mucin, which may provide additional protection to mucosa during acid related challenge.

38

Page 39: Product Manual Acute

Rabee-DCompositionRabee –D is a capsule containing Rabeprazole sodium 20 mg (as enteric coated pellets) and Domperidone BP 30 mg (as sustained release pellets).

DescriptionRabeprazole is an oral drug that is used for the treatment of conditions caused by acid. It is in a class of drugs called proton pump inhibitors or PPIs. Domperidone is a dopamine antagonist with anti emetic and gastroprokinetic properties.

MOARabeprazole act by irreversibly blocking the hydrogen/potassium adenosine triphosphatase enzyme system (the H+/K+ ATPase, or more commonly just gastric proton pump) of the gastric parietal cell. The proton pump is the terminal stage in gastric acid secretion, being directly responsible for secreting H+ ions into the gastric lumen, making it an ideal target for inhibiting acid secretion. Targeting the terminal-step in acid production, as well as the irreversible nature of the inhibition, results in up to 99% reduction of gastric acid secretion.The mechanism of action of domperidone is related to its peripheral dopamine receptor blocking properties.

Domperidone does not readily cross the blood-brain barrier and therefore is not expected to have central effects.

Pharmacology Rabeprazole : Refer Rabee

Domperidone Absorption: Domperidone is rapidly absorbedProtein Binding: 91-93%Metabolism: HepaticExcretion: Approximately 31%in urine, 66% in the feces.Half life 7-9 hours

Contraindication

The fixed dose combination of Rabeprazole and Domperidone is contraindicated in patients with known hypersensitivity to either drug or their substitutes. Also fixed dose combination is contraindicated in the presence of gastro-intestinal hemorrhage, obstruction or perforation.

Drug to drug interactionDrugs like warfarin, theophylline, diazepam, phenytoin, anticholinergic drugs, Antimuscarinic agents and opiod analgesics must be used with caution while administering this combination.

39

Page 40: Product Manual Acute

Adverse Drug ReactionIn general, both the drugs separately are well tolerated. Following adverse drug reactions may occur with this fixed drug combination headache, asthenia, skin rash, diarrhea, flatulence, constipation and dry mouth.

Indication1. Dyspepsia 2. GERD 3. Nausea associated with acid peptic disorders 4. Post-operative nausea and vomiting 5. Chronic gastritis

Dosage & Administration

Indication Dose

GERD in adults One cap. daily for 4-8 weeks & If healing does not occur after 8 weeks, another 8 week course may be considered.

Heartburn One cap. daily for 4 weeks and an additional 4 weeks if symptoms do not resolve.

Capsule should be swallowed whole and should not be crushed, split or chewed. Rabeprazole can be taken with or without meals since food has little effect on its absorption.

RATIONALE OF COMBINATION THERAPY

1. Hyperacidity and Hypomotility are common GIT problems and frequently coexist together.

2. Excess hydrochloric acid and defective clearance of the acid and other gastric content from the stomach together or individually give rise to nausea, vomiting and upper abdomen discomfort due to irritation of gastric mucosa.

3. Only acid suppression or only prokinetic therapy by itself would not serve the purpose.

4. Rabeprazole a PPI is a drug of choice for acid suppression and Domperidone is drug of choice for stimulation of gastric motility.

5. Both the drugs are devoid of any major side effects. Domperidone does not cross Blood Brain Barrier (BBB), so no extra pyramidal syndrome.

6. Both the drugs are in pellet form. Different colour pellets are packed in same

40

Page 41: Product Manual Acute

capsule, so the compliance of the patient will be excellent.

7. Domperidone has short half-life, which makes it necessary to take it three times a day. Therefore it has been formulated as sustained release pellets. The advantages of domperidone sustained release pellets include round the clock symptom control, better patient compliance with fewer side effects.

8. Rabeprazole 20mg is formulated as enteric-coated pellets. It reduces fluctuations in drug plasma concentrations improves effectiveness and controls the site of drug delivery in the GI tract.

9. Combination of Rabeprazole and Domperidone gives a complete symptomatic relief from Dyspepsia, heartburn, and Acid-Pepsin disorder associated with nausea, vomiting and epigastric pain.

USP’S OF RABEE -DA. • Precise Microtechnology

Uniform size pellets and less than 1mm that offers low dose dumping and uniform absorption

B. • Precise Chemistry i. 24 hours controlled release Domperidone.ii. 10mg out of 30mg Domperidone in Rabee-D is released in

the 1st hour for faster action.C. Once a day dosage.D. Pellet diameter is less than 1.0mm to 1.5 mm hence the pellets can pass

the pyloric sphincter even when it is closed.

Precise 4 dimensional action 1. Increases LES pressure that prevents reflux.

2. Increases mucin and mucus secretion that improves GI protection.

3. Accelerates Gastric emptying that reduces bloating. 4. Faster Inhibition of proton pump that controls hyperacidity and epigastric

pain.

CompetitorBrands Marketed by CompositionAlgibra – D CFL Each hard gelatin capsule contains

Rabeprazole sodium (as enteric coated tablet) 20 mg, Domperidone B.P (tablet) 20 mg SR, Domperidone BP (tablet) 10mg IR

Rabemac DSR

Macleods Each hard gelatin capsule contains Rabeprazole sodium (as enteric coated tablet) 20 mg, Domperidone B.P (tablet)

41

Page 42: Product Manual Acute

20 mg SR, Domperidone BP (tablet) 10mg IR

Rabicip-D Cipla Each capsule contains Rabeprazole Sodium 20 mg (as enteric coated pellets)+ Domperidone BP 30 mg (as sustained release pellets)

Veloz D Torrent Each capsule contains Rabeprazole Sodium 20 mg + Domperidone 30 mg SR

42

Page 43: Product Manual Acute

Rabee ISR

Product Manual: Rabeprazole 20 mg + Itopride ER 150 mg

PROKINETICS

In general, GI motility is mainly described as peristalsis. Peristalsis is controlled by 3 mechanisms.1. Mechanical - Presence of bolus of food or distension of gut stimulates peristalsis.2. Nervous - It is central in origin. The vagus nerves innervate the smooth muscle through the

myentric plexus. The myentric plexus is the programmer for all motility programs in the GIT e.g. it regulates the following functions.i. Reservoir function - e.g. in fundus of stomach.ii. Mixing function - e.g.in small intestine.iii. Barrier function e.g. in LESiv. Propulsive function at all levels.The inputs come from mechanical and chemical receptors in gut wall & CNS. Hence it is called "little brain" or "gut brain".

3. Chemical - Through neurotransmitters mainly acetylcholine.

Any impairment in GI motility leads to reflux of the contents, vomiting, nausea, and constipation. Also symptoms like heartburn, nausea, vomiting, regurgitation, dyspepsia, pain.

Other condition in which there can be GI motility impairment is gastroparesis i.e. paralysis of gut wall. It presents itself as a motility disorder of poor gastric emptying.

The drugs used in the treatment of these hypomotility conditions are prokinetics. Antidopaminergic drugs can also be used but they may precipitate side effects.

What is Itopride?

Itopride is a prokinetic benzamide derivative. This drug inhibits dopamine and has a gastrokinetic effect (result in increased gastrointestinal motility)

What are the pharmacological actions of Itopride?

Itopride increases acetylcholine concentrations by inhibiting dopamine D2 receptors and acetylcholinesterase. Higher acetylcholine increases GI peristalsis, increases the lower esophageal sphincter pressure, stimulates gastric motility, accelerates gastric emptying, and improves gastro-duodenal coordination.

Clinical Use and Dosage:

Typically, itopride is indicated in the treatment of GI symptoms caused by reduced GI motility:

dyspepsia of a non-ulcer type (gastric "fullness", discomfort, and possible pain) anorexia heartburn regurgitation bloating

43

Page 44: Product Manual Acute

nausea and vomiting other possible gastric, prolactin, or dopamine related conditions

Typical adult dosage is usually 150mg/24hrs in 3 divided doses. However, Itopride ER 150 mg is administered once a day. The dose is usually taken on an empty stomach about an hour before meals. However, the dosage and details of administration may vary depending on the patient’s age, symptoms, and other factors.

Itopride was shown to significantly improve symptoms in patients with functional dyspepsia and motility disorders in placebo-controlled trials.

Contraindications and precautions

Itopride is contraindicated in hypersensitivity to itopride or benzamides; lactation, GI hemorrhage, obstruction or perforation. Itopride may not be indicated for those suffering from Parkinson's disease or other conditions involving dopamine regulation issues. Itopride should be used with special caution in the young and the elderly. Little information is available at this time regarding the safe use of itopride during pregnancy.

Adverse drug reactions

Some common side-effects of itopride may include: rash, diarrhoea, giddiness, exhaustion, back or chest pain, increased salivation, constipation, abdominal pain, headache, sleeping disorders, dizziness, galactorrhea, and gynecomastia.

Other side-effects may also be present.

Leukopenia, a reduction in the normal level of white blood cells, can be a potentially life-threatening reaction to itopride.

PROTON PUMP INHIBITORS

PPIs act by inhibiting the proton pump H+-K+-ATPase which is the ultimate mediator of gastric acid secretion. As the name suggests H+-K+-ATPase is an enzyme which utilizes ATP to catalyse the outward transport of H+ in exchange for the inward transport of K+.

All available Pips viz. Omeprazole, lansoprazole and pantoprazole being weak bases, accumulate in the acidic compartment of parietal cells and get highly ionized at low pH. They are prodrugs, which are rapidly converted to the active form,, cationic sulfenamides. These bind covalently to the cysteine molecules of H+-K+-ATPase, thus blocking the H+-K+-channels of the enzymes involved in the expulsion of H in exchange for K . Since activation of H+-K+-ATPase is the terminal step in the gastric acid secretion, PPIs inhibit HCl acid secretion in response to all stimulii.

What is Rabeprazole?

Rabeprazole is an antiulcer drug in the class of proton pump inhibitors.

44

Page 45: Product Manual Acute

Clinical Use and Dosage:

Gastric ulcer Peptic ulcer (PUD) Maintenance of Healing of Erosive or Ulcerative GERD Healing of Erosive and Ulcerative GERD Healing of Duodenal Ulcers. Treatment of Symptomatic GERD Treatment of Pathological Hypersecretory conditions (Zollinger-Ellison) Helicobactor Pylori Eradication to Reduce Risk of Duodenal Ulcer Recurrence

It is given 20 Mg Once a day.

Contraindications and precautions

Hypersensitivity to Rabeprazole, substituted benzimidazoles or any of components of its pharmaceutical forms.

Pregnancy Lactation

Adverse drug reactions

Some common side-effects of Rabeprazole may include: headache, diarrhea , vomiting, nausea, abdominal pains , constipation, meteorism, dry mouth, increased or decreased appetite, asthenia , headache, anxiety, sleeplessness, vertigo, thrombocytopenia, granulocytopenia, leukocytopenia, skin eruption, erythema, myalgia, arthralgia, muscle or bone pain

Other side-effects may also be present.

Pharmacokinetics:

Rabeprazole + Itopride Rationale for combination:In GERD, treatment aims at decreasing the amount of reflux or reducing damage to the lining of the esophagus from refluxed materials. Thus, Itopride by increasing acetylcholine concentrations by inhibiting dopamine D2 receptors and acetylcholinesterase, increases GI peristalsis, increases the lower esophageal sphincter pressure, stimulates gastric motility, accelerates gastric emptying, and improves gastro-duodenal coordination and thus decreases the amount of reflex. On other hand Rabeprazole reduces the damage to the esophagus lining by

Bioavailability 52%

Metabolism Hepatic

Half life 1 - 1.5 hours

Excretion Renal

45

Page 46: Product Manual Acute

suppressing the gastric acid secretion by inhibiting the gastric H+-K+-ATPase at the secretory surface of the gastric parietal cell. Moreover, Rabeprazole and ER Itopride are given as once a day dosage and thus ideal for combination.

Indication and Dosage: 1 capsule once daily before food in patiens wih GERD.

Contraindication:

Hypersensitivity Lactation

It should b used with caution in patients with severe hepatic impairment and in pregnancy.

Drug Inteaction:

Rabeprole increases eliminationT ½ of digoxin, decreases effects with aminoglutethimide, carbamazepine, phenotoin and rifampin and reduces aborption of ketoconazole and itracnazole.

Anti cholinergic agents reduces the action of Itopride

Adverse Drug Reaction:

Headache, diarrhoea, dizziness, rash.

Potential Life threatening: Anaphylaxis, agranulocytosis

TRICAINE- MPS

ANTACIDS

These are oral medications that neutralize the amount of acid present within the stomach or duodenum or esophagus. These medications act quickly but by different mechanisms than histamine to receptor antagonists and proton pump inhibitors. Antacids typically act by directly neutralizing the HCL (hydrochloric acid) present within the stomach or duodenum or esophagus.

46

Page 47: Product Manual Acute

COMPOSITION

Aluminum hydroxide 300mgMagnesium hydroxide 150 mgSimethicone 125 mg Oxethazaine 10 mg

PHARMACODYNAMICS

Alumina gel and magnesium hydroxide react chemically to neutralize or buffer existing quantities of acid, but have no direct effect on its production.

Oxethazaine exerts a prolonged topical anaesthetic action.Oxethazaine is a topical anaesthetic, which, when applied to the mucous membranes produces a more potent anaesthesia of longer duration than either cocaine hydrochloride or lidocaine hydrochloride. Simethicone is used to help relieve pain and bloating caused by trapped wind. It works by bringing together all the small bubbles of gas to form a large bubble, which is expelled either by belching or flatulence.

PHARMACOKINETICS

Studies have shown that a small amount of aluminium from aluminium hydroxide is absorbed from the intestine. Approximately 10% of the magnesium in agnesium hydroxide is absorbed from the intestine.After oral administration of oxethazaine contained in 10 mL of alumina gel with magnesium hydroxide, the peak oxethazaine plasma level was approximately 20 ng/mL and occurred about one hour after dosing.Oxethazaine undergoes rapid and extensive biotransformation resulting in a short plasma half-life of approximately one hour. Less than 0.1% unchanged oxethazaine was recovered in the urine within 24 hours. Major metabolites were beta-hydroxy-mephentermine and beta-hydroxy-phentermine. Mephentermine and phentermine appeared in the plasma in pharmacologically insignificant amounts and their cumulative 24-hour urinary excretion was less than 0.1% of the dose administered.Simethicone not absorbed.

INDICATIONS

It acts as an antacid in dyspepsia and is used for the symptomatic relief of hyperacidity associated with peptic ulcer, gastritis, esophageal reflux with heartburn. It may be of benefit if symptomatic relief could not be obtained with antacid therapy alone.

47

Page 48: Product Manual Acute

CONTRAINDICATIONS

Tricaine – MPS should not be given to any patient who has demonstrated sensitivity to it.

Do not use Tricaine – MPS if patient is presently taking a prescription antibiotic drug containing any form of tetracycline.

Tricaine – MPS contra-indicated in patients with symptoms of appendicitis since these medicines may increase the danger of perforation or rupture due to their constipating or laxative effects.

The use of aluminium-containing antacids (except those containing aluminium phosphate) is contra-indicated in patients with hypophosphataemia due to the phosphate binding properties of aluminium salts.

The use of magnesium-containing antacids is contra-indicated in patients with severe renal function impairment due to increased danger of occurrence of hypermagnesaemia.

SAFETY IN PREGNANCY AND LACTATION HAS NOT BEEN ESTABLISHED.

RECOMMENDED DOSAGE

The recommended Tricaine – MPS adult oral dose is one to two 5 ml measures, four times daily, 15 minutes before meals and at bedtime. Do not exceed the recommended dosage. Tricaine - MPS should preferably be taken undiluted; however, if desired, a sip of water may follow it.

ADVERSE DRUG REACTIONS (ADRs)

Medicines and their possible side effects can affect individual people in different ways. The following are some of the side effects that are known to be associated with Tricaine – MPS. Because a side effect is stated here, it does not mean that all people using this medicine will experience that or any side effect. Disturbances of the gut such as diarrhoea, constipation, nausea, vomiting or abdominal pain

DRUG INTERACTIONSFluoroquinolones (medicine for infection)-Antacids may decrease the effects of these medicines Isoniazid taken by mouth (e.g., INH)-Aluminum-containing antacids may decrease the effects of isoniazid; isoniazid should be taken at least 1 hour before or after the antacid

48

Page 49: Product Manual Acute

Ketoconazole -Antacids may decrease the effects of ketoconazole, should be taken 3 hours before the antacid Tetracyclines (medicine for infection) taken by mouth-Use with antacids may decrease the effects of both medicines; antacids should not be taken within 3 to 4 hours of tetracyclines PRESENTATION

Tricaine MPS Gel - Each 180ml contains Oxethazaine 10mg + Aluminium Hydroxide Gel

equivalent to Dried Aluminium Hydroxide Gel 300mg Paste equivalent to Magnesium Hydroxide 150mg + Simethicone 40mg

Bottle of 180ml

USP’S OF TRICAINE – MPS

Al (OH)3: Sustained Acid neutralization

Mg (OH)2:Rapid Acid neutralization

Balanced 2:1 ratio Laxative (Mg) & constipation (Al) effects balanced

Simethicone: Anti-flatulent effect

Oxethazaine: pain relief by local anesthesia & reduced acid secretion

American mint flavor: Better patient compliance

Daslin NF Cough Syrup

Composition:

Each 5ml contains:Loratadine HCL USP 5 mgAmbroxol HCl BP 30 mgGuaiphenesin IP 50 mgMenthol IP 0.5 mg

49

Page 50: Product Manual Acute

Loratidine:Loratidine, a piperidine derivative related to azatadine is a non-acting, non-sedating antihistamine with no significant muscaranic activity. It is used for the symptomatic relief of allergic conditions in Rhinitis.

In Seasonal allergic Rhinitis, the recommended dosage of Loratidine in adults is 10 mg once daily.

In children aged between 2-5 years of age the recommended dosage is 5 mg once daily.

Ambroxol:

Ambroxol is a metabolite of Bromhexine. It is a mucolytic agent. Studies showed that it enhances both bronchial glandular cell secretions. These secretions get mixed with the thick mucus thereby reducing its viscosity and helping easy expectoration. It also stimulates cilliary motility and accelerates mucocilliary transport.

Studies have also shown that Ambroxol affects the secretomotor activity of serous glands, facilitates the repair of bronchial epithelium and accelerates mucociliary transport and clearance.

It has daily dose of 30 to 120 mg by mouth in to 2 to 3 divided doses. It is rapidly absorbed from the gastrointestinal tract and has a very high bioavailability.Ambroxol is been seen to increase the concentration of antibiotics in the lungs, when co – prescribed.

Guaiphenesin:Guaiphenesin is used as an expectorant in symptomatic management of coughs associated with common cold, bronchitis, laryngitis, pharangytis, pertusis, influenza, measles, and coughs provoked by chronic paranasal sinusitis.Guaiphenesin is an expectorant, which increases the respiratory tract fluid and helps loosen the mucus and bronchial secretions. By reducing the viscosity of secretion, guaiphenesin increases the efficiency of the mucociliary mechanism in removing accumulated secretion from the airways. It has been frequently used in the management of productive cough.

Doses recommended:

Adults: Oral Doses of 200 to 400 mg every 4 hoursChildren 6 to 12 years: 100 to 200 mg every 4 hours.Children 2 to 6 years: 50 to 100 mg every 4 hours.

50

Page 51: Product Manual Acute

Menthol:Provides soothing actions.

Indications:

In Productive cough associated with seasonal allergic rhinitis & perennial allergic rhinitis.

In allergic bronchial asthma. In drug induced allergy.

Dosage:Adults & children above 12 years - 1 to 2 teaspoonful 2 times daily

Children between 6 to 12 years – ½ to 1 teaspoonful 2 times daily

Children between 2 to 6 years – ½ to 1 teaspoonful 2 times daily

Unique Selling Point Of Daslin NF.

Unique combination, one of the best antihistamine, - Loratidine not only takes care of allergic productive cough but also inhibits histamine induced bronchoconstriction.

Sedation free cough formulae which can be easily prescribed to working class.

Sugar free base, which can be prescribed to diabetic, & to calorie conscious patients.

Improves pulmonary function without tremors, thus offering a tremor free treatment.

Only such combination available with menthol.

51

Page 52: Product Manual Acute

Daslin Cd Cough SyrupComposition:Each 5ml contains:Chlopheniramine maleate. I.P. 4 mgCodeine Phosphate. IP 10 mg

Chlorpheniramine maleate:

Chlorpheniramine maleate is an alkyl amine (propylamine) – derivative, first generation antihistamine. It is an H 1 receptor antagonist. These are to be administered orally.

Dosage: Chlorpheniramine maleate is been given by mouth in doses of 4 mg every 4 to 6 hrs. up to maximum dose of 24 mg daily , Doses for children are 1 to 2 yrs. , 1 mg twice daily; 2 to 5 years, 1 mg every 4 to 6 hours (maximum 6 mg daily) ; 6 to 12 years , 2 mg every 4 to 6 hrs (maximum 12 mg daily).

Codeine Phosphate:Codeine inhibits the receptor in the cough center of the medulla oblongata and acting on the brain to reduce the cough reflex, without the suppression of the respiratory center. Codeine is used in combination with other antitussives or expectorants, in the symptomatic relief of non-productive cough. Since the cough reflex may be useful physiologic mechanism, which clears the respiratory passages of foreign material and excess of secretion and may aid in preventing or reversing atlectasis, cough suppressants should not be used indiscriminately.Dosage: Codeine preparation should be given in the smallest effective dose and infrequently as possible to minimize the development of tolerance and physical dependence. Reduced dosage is indicated in poor risk patients, in very young or very old patients, and in-patients receiving other CNS depressants.

Dosage:The usual oral antitussive dosage of Codeine Phosphate for adults and children and of 12 years and older is 10- 20 mg every 4 to 6 hrs not to exceed 120 mg daily.The usual antitussive dosage for children 6 to 12 years of age is 5-10 mg every 4 to 6 hrs not to exceed 60 mg daily.The usual antitussive dosage for children 2 to younger than 6 years of age is 1 mg/Kg. Daily given in 4 equally divided doses every 4 – 6 hrs.

Indications:

In Allergic & Non specific dry cough. Tubercular cough.

52

Page 53: Product Manual Acute

Haemoptysis. Nighttime cough. Post Surgical cough

RINOSTAT XL0.1% Nasal Drops

Composition;

Xylometazoline Hydrochloride IP 0.1% w/v.In an aqueous isotonic solution using purified water i.p.

Preservative: Benzalkolium chloride USP 0.011% w/v.

Dosage: Adults and Children over 6 years: 2-3 drops into each nostril per application.

A total of 3-4 applications per day are usually sufficient.

Rinostat XL 3 drops 3 times for 3 days provides 333 express relief from nasal congestion.

Rinostat XL provides 333 express relief within 10 minutes without any rebound congestion.

Xylometazoline: Xylomeatzoline is a directly acting sympathomimetic with marked alpha adrenegeric activity. It is a vasoconstrictor, which reduces swelling and congestion when applied to mucous membranes. The effect begins from 5 to 10 minutes.

Indication:

Acute or chronic Rhinitis

Acute Sinusitis.

Common cold.

53

Page 54: Product Manual Acute

Rinostat Plus

Rinostat Plus is available in tablets and Syrup form

COMPOSITION: For tablets:Each uncoated tablet contains: Acetaminophen IP - 500 mgPhenylpropanolamine HCl BP - 25 mgChlorpheniramine Maleate IP - 4 mgExcipients - q.s.

For Syrup:Each 5 ml contains:Acetaminophen IP – 125 mgPhenylpropanolamine HCl BP – 12.5 mgChlorpheniramine maleate IP – 1 mg

Indications: Symptomatic relief of common cold and other upper respiratory infections

such as fever, aches, pains, nasal and sinus congestion, etc. 7 symptoms of COLD –

Runny nose, Nasal congestion, Sneezing, Watery eyes, Body aches, Headache, Fever

FEATURES:Rinostat Plus is paracetamol + CPM combination (analgesic and anti-histamine). Therefore, can be used for symptomatic relief of common cold. Rinostat Plus Syrup is available in rose flavour.

54

Page 55: Product Manual Acute

Pro-Banthine

COMPOSITION:Each sugar-coated tablet contains:

Propantheline Bromide IP … 15 mg

What is Pro-Banthine?Pro-Banthine is an anticholinergic drug.

What is anticholinergic drug?An anticholinergic drug is the one that blocks the neurotransmitter called Acetylcholine (Ach).

Thereby, reducing the effects mediated by Ach on its receptors in neurons (eg: reducing the spasms of the smooth muscle).

These drugs act on Ach receptors that are present on smooth muscle in the gut, bladder, etc. This smooth muscle is not under voluntary control.

INDICATIONSIrritable bowel syndrome (IBS)Urinary incontinence and enuresisTo reduce salivation during dental procedures

What is IBS?

IBS – a functional bowel disorder in which abdominal pain or discomfort is associated with defecation or a change in bowel habit and with features of disordered defecation.

Symptoms of IBSThe most common symptom is abdominal pain associated with diarrhea, constipation or both.

• Other symptoms include gas, bloating, cramping and indigestion.

Factors that trigger IBS Symptoms:• Stress• Foods like milk products, chocolate, caffeine,carbonated drinks, alcohol,

and food with high fat content.

Some facts about IBS:• Constitutes a major health problem with gastrointestinal symptoms • The cause of IBS is unknown.• The condition is more frequent in women.

55

Page 56: Product Manual Acute

What is the role of Role of Ach in the gut?Ach binds to the Ach-receptors in the gut & causes gastric motility. Excess of Ach in gut increases the gastric motility & gives the feeling of frequent defecation.

How does Pro-Banthine help in IBS?• Pro-Banthine works by blocking Ach receptors in gut. This prevents the

action of Ach. Hence, causes smooth muscle to relax .& prevents the muscle spasms occurring in IBS. By relaxing the gut muscle, Pro-Banthine relieves the IBS symptoms.

How does Pro-Banthine help in Urinary Incontinence & Enuresis?Urinary Incontinence (UI):• Any involuntary leakage of urine.

Enuresis (Bed-wetting):• A repeated involuntary or unintentional discharge of urine into bed or

clothes beyond the expected age for controlling urination.

In normal condition Ach. Helps in the contraction of smooth muscle of urinary bladder & helps in urination but when the level of Ach. increases then it causes UI & Enuresis.Pro-Banthine works by blocking Ach receptors in urinary bladder. This prevents the action of Ach hence, causes smooth muscle to relax & prevents the muscle spasms occurring in bladder & prevents the involuntary spasms which can allow leakage of urine from the bladder.

DOSAGE AND ADMINISTRATION: For IBS: 15 mg tid For Urinary Incontinence: 15 mg tid For Enuresis: 15 mg tid and 30 mg during bed-time To reduce salivation during dental surgery:

30 mg one hour before surgery and 15 mg tid Hyperhidrosis: 15 mg tid

_______________

56